scholarly journals Loss of HBsAg in Patients with High Levels of HBV-DNA During Treatment with Nucleoside or Nucleotide Analogs

2020 ◽  
Vol 20 (10) ◽  
Author(s):  
Tadeusz W Lapinski ◽  
Monika Pazgan-Simon ◽  
Robert Plesniak ◽  
Barbara Sobala-Szczygiel
Keyword(s):  
Antiviral Treatment ◽  
Virus Production ◽  
Pegylated Interferon ◽  
Hbv Dna ◽  
Nucleotide Analogs ◽  
Production Methods ◽  
Ifn Therapy ◽  
Pegylated Interferon Alfa ◽  
Chronic Hbv ◽  
Positive Hbeag

Background: HBsAg is synthesized in the endoplasmic reticulum and is necessary for the formation of complete HBV particles. A decreased synthesis of this antigen leads to an intracellular inhibition of virus production. Methods: The study aimed to assess the incidence of HBsAg elimination among 1,290 patients who suffered from chronic HBV infection undergoing an antiviral treatment with nucleoside or nucleotide analogs (NAs). Furthermore, possible predictive factors for this elimination were analyzed. Results: A permanent HBsAg loss was confirmed in 3% of the patients, which was more frequent in men than in women (4.4% vs. 1.9%; P = 0.009). The HBsAg elimination occurred in 5% of HBeAg (+) patients and 2.8% of HBeAg (-) patients. The age of patients whose HBsAg was eliminated was higher than the age of the remaining patients (60 vs. 51 y/o). The effect of initially used pegylated interferon alfa (PEG-IFN) therapy on the HBsAg elimination was not observed. It occurred with the use of entecavir (ETV) and tenofovir (TDF); however, among patients treated with ETV, HBsAg was significantly more often eliminated in HBeAg (+) patients. Conclusions: The HBsAg elimination in patients undergoing antiviral treatment occurs more often in men, patients with positive HBeAg before treatment, individuals above 60 years, and patients treated with ETV.

scholarly journals Antiviral treatment of hepatitis C in Serbian prison setting: Medical treatment outcomes and patients’ adherence

2016 ◽  
Vol 69 (3-4) ◽  
pp. 85-91 ◽  
Author(s):  
Jasmina Simonovic-Babic ◽  
Ksenija Bojovic ◽  
Dragan Delic ◽  
Natasa Katanic ◽  
Nikola Mitrovic ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Viral Infection ◽  
Sustained Virological Response ◽  
Virological Response ◽  
Antiviral Treatment ◽  
Pegylated Interferon ◽  
Interferon Alfa ◽  
Genotype 1 ◽  
Pegylated Interferon Plus Ribavirin ◽  
Pegylated Interferon Alfa

Introduction. Seroprevlence of chronic hepatitis C viral infection in correctional facilities ranges from 16% to 49%. However, there are only very limited data available on the course of hepatitis C viral infection and outcomes of treatment with pegylated interferon plus ribavirin in correctional settings. The aim of this study was to assess the feasibility and effectiveness of use of pegylated interferon plus ribavirin treatment in the Serbian correctional setting. Material and Methods. The study sample consisted of the patients with hepatitis C hospitalized in the Special Hospital for Prisoners in Belgrade (Serbia) during 2007-2013. Health authorities approved treatment for 32 patients out of 76 treatment-naive patients referred to this institution. The patients (N=32) received 180 mcg pegylated interferon alfa-2a once a week plus oral ribavirin in dosage of 800mg or 1000/1200 mg/day for 24 or 48-week treatment. All patients who completed therapy were assessed at the end of an additional 24-week treatment-free period for a sustained virological response. Results. Sustained virological response was achieved in 53.8% of hepatitis C viral infection genotype 1 patients and in 73.3% and 66.6% of patients with hepatitis C viral infection genotype 3 and 4, respectively. One patient with mixed genotype (1, 2) did not achieve sustained virological response. The overall safety profile of the treatment regimen was very good. The incidence of influenza-like symptoms and depression were low. A serious adverse event was recorded only in 6.4% of patients. Conclusion. The results showed that pegylated interferon alfa-2a plus ribavirin given once a week was well tolerated among prisoners and the regimen had the same adherence and effectiveness as in general population.

scholarly journals Incidence And Predictors of Relapse After Stopping Antiviral Therapy In Pediatric Chronic Hepatitis B

2021 ◽  
Author(s):  
Piyush Upadhyay ◽  
Bikrant Bihari Lal ◽  
Vikrant Sood ◽  
Rajeev Khanna ◽  
Ekta Gupta ◽  
...  
Keyword(s):  
Antiviral Therapy ◽  
Activity Index ◽  
Antiviral Treatment ◽  
Sequential Therapy ◽  
Pegylated Interferon ◽  
Hbv Dna ◽  
Biochemical Relapse ◽  
Interferon Alpha 2B ◽  
Virological Relapse ◽  
Normal Alanine Aminotransferase

Abstract Objective: The objective was to evaluate the incidence of relapse after stopping antiviral therapy and to identify the predictors of relapse. Methods: All HBsAg positive children with who had been on antivirals for at least 2 years with undetectable HBV-DNA and normal alanine-aminotransferase (ALT) on three consecutive occasions over last 12 months were included. Antivirals were stopped if liver biopsy showed histological activity index <5 and fibrosis (metavir) <3. Children were monitored for virological relapse (elevation of HBV-DNA >2000 IU/mL) and biochemical relapse (ALT levels >2 × upper limit of normal (ULN)). Those having biochemical relapse were started on pegylated interferon alpha-2b based sequential therapy. Results: Antivirals were stopped in 31 HBsAg positive children. Virological and biochemical relapse was seen in 12 (38.7%) and 5 (16.1%) children within 12 months of stopping antiviral treatment. Majority of virological relapse occurred within a month and biochemical relapses within 6 months of stopping therapy. HBeAg positive status at the time of stopping antiviral therapy (HR: 7.206, p =0.005) and longer time taken for HBV-DNA to become undetectable while on antivirals (HR: 1.030, p=0.037) were found to be the 2 independent predictors of relapse after stopping antiviral treatment. Conclusion: Discontinuation of antiviral treatment in children with CHB resulted in relapse in one third of the patients. Relapse was more common in those with HBeAg positivity at the time of stopping therapy and in those with longer time taken for HBV-DNA to become undetectable on antivirals.

scholarly journals Peginterferon and Entecavir combination therapy improves outcome of non-early response Hepatitis B e antigen-positive patients

2020 ◽  
Author(s):  
Lu Chen ◽  
Lanyi Lin ◽  
Huijuan Zhou ◽  
Weiliang Tang ◽  
Hui Wang ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Combination Therapy ◽  
Treatment Outcomes ◽  
Combined Therapy ◽  
Pegylated Interferon ◽  
Early Response ◽  
Hbv Dna ◽  
Hepatitis B E Antigen ◽  
Treatment Naïve ◽  
Positive Hbeag

Abstract Background It is still controversial that the efficacy of nucleot(s)ide analogs (NAs) and pegylated interferon (PegIFN) combination therapy for hepatitis B e antigen positive (HBeAg +) patients. It was assessed whether PegIFN and entecavir (ETV) combination therapy could bring more benefit for HBeAg + patients. Methods The treatment naïve HBeAg + patients initiated with PegIFN alfa-2a (PegIFNα-2a) for 24 weeks without early response (early response: HBsAg &lt; 1500 IU/mL and HBV DNA &lt; 10 5 copies/mL) were recruited in the current study. Among total of 94 patients, 51 were continued with PegIFNα-2a monotherapy, 43 were offered PegIFNα-2a and ETV combined therapy. Results It was demonstrated that better outcomes in response to the combined therapy compared to that of the monotherapy, including more HBsAg decline and loss, HBV DNA decline and HBeAg clearance. Importantly, the patients with HBsAg levels between 1500 - 20,000 IU/mL initially or between 5000 - 20000 IU/mL after 24 weeks of PegIFNα-2a were more benefit from the combined therapy, compared to that of monotherapy. Conclusions The combined therapy of PegIFNα-2a and ETV is more efficacy for HBeAg + patients without early response to PegIFN monotherapy, and the HBsAg levels are a good predictor of the treatment outcomes.

scholarly journals AST and HBeAg Level Can Help to Distinguish Non-Minimal Liver Inflammation in Persistently Normal Alanine Aminotransferase of Chronic HBV Infection

2020 ◽  
Vol 20 (10) ◽  
Author(s):  
Lu Zhang ◽  
Ming Hui LI ◽  
Wei Yi ◽  
Yao Lu ◽  
Shu-Ling Wu ◽  
...  
Keyword(s):  
Antiviral Treatment ◽  
Multivariate Regression Analysis ◽  
Serum Markers ◽  
Hbv Dna ◽  
Influential Factors ◽  
Hbv Infection ◽  
Liver Inflammation ◽  
Chronic Hbv Infection ◽  
Chronic Hbv ◽  
Inflammation Group

Objectives: The current study aimed to investigate the characteristics of HBV serum markers (HBsAg, HBeAg), biochemical indicators, HBV DNA, and the age to distinguish minimal from non-minimal liver histological inflammation group in HBeAg-positive chronic HBV-infected patients with ALT≤ 1ULN (40U/L). Methods: The HBeAg-positive patients with treatment-naïve hospitalized at Ditan hospital from January 2008 to January 2017 are investigated. Patients were separated into two groups of minimal and non-minimal (mild and moderate) histological inflammation group by liver biopsy specimens. Data were analyzed using the SPSS package. Results: There were both positive (age, ALT, and AST) and negative correlation factors (serum HBsAg, HBeAg, or HBV DNA quantitation) to the liver inflammation grades. Multivariate regression analysis indicated that HBeAg (P < 0.001, b = -0.554, Exp (B) = 0.575) and AST (P = 0.003, b = 0.074, Exp (B) = 1.077) were independent influential factors. The cutoff values of HBeAg and AST were separately 2.85 Log10S/CO (AUC0.724, Sensitivity64%, Specificity79%), 28U/L (AUC0.726, Sensitivity68%, Specificity 78%) to distinguish Minimal from Non-minimal liver histological inflammation in chronic HBV-infected patients with ALT ≤ 1 ULN (40U/L). Conclusions: In total, 31.34% (115/367) of patients with chronic HBV infection who had non-minimal (mild and moderate) liver histological inflammation reached the required inflammation levels for antiviral treatment in HBeAg-positive patients with persistently normal ALT. HBeAg (cutoff < 2.85 Log10S/CO) and AST (cutoff > 28 U/L) were the independent influential factors of predicting non-minimal liver inflammation with ALT ≤ 1 ULN (40U/L).

Treatment of pegylated-interferon alfa-2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation

2014 ◽  
Vol 20 (2) ◽  
pp. 217-224
Author(s):  
Qingxian Cai ◽  
Fengjuan Chen ◽  
Xiaoqiong Shao ◽  
Xiaohong Zhang ◽  
Zhixin Zhao ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Acute Exacerbation ◽  
Chronic Hepatitis B ◽  
Pegylated Interferon ◽  
Hbv Dna ◽  
Interferon Alfa ◽  
Pegylated Interferon Alfa
Sign in / Sign up

Export Citation Format

Share Document